Cystic Fibrosis Plasma

Cystic Fibrosis Plasma for CFTR and Chronic Airway Inflammation Research

Cystic Fibrosis Plasma is collected from IRB-consented donors clinically diagnosed with cystic fibrosis (CF) and processed within one day of collection to preserve labile analytes such as cytokines, proteins, and metabolites. Cryopreserved and available in custom aliquots, this human plasma supports research into CFTR-driven disease biology, chronic neutrophilic inflammation, nutritional status, and modulator therapy response. Research Use Only (RUO).

Molecular Basis and Why Plasma

• Cystic fibrosis is an autosomal recessive monogenic disease caused by variants in CFTR, which encodes a cAMP-regulated chloride and bicarbonate channel at the apical surface of epithelial cells.
• Loss of CFTR function dehydrates airway surface liquid and impairs mucociliary clearance, producing viscous secretions, mucus plugging, chronic bacterial airway infection, and progressive bronchiectasis.
• F508del is the most common disease-causing variant, and variant class determines eligibility for CFTR modulator therapy, so genotype is central to study design.
• CF is a multi-organ disease: exocrine pancreatic insufficiency, malabsorption of fat-soluble vitamins, CF-related diabetes, CF liver disease, and impaired growth are all common.
• The airway inflammatory response in CF is predominantly neutrophilic and is accompanied by measurable systemic inflammatory mediators, making plasma useful for circulating cytokine, acute-phase, and proteomic readouts.
• Plasma is acellular and therefore appropriate for soluble biomarker, metabolomic, and nutritional analyte work rather than cell-based assays.

Donor Stratification Available

• CFTR genotype where documented, including F508del homozygous and heterozygous donors
• CFTR modulator therapy status: on elexacaftor/tezacaftor/ivacaftor, on other modulator, or modulator-naive
• Pancreatic sufficiency versus insufficiency
• Lung function category and documented exacerbation history
• Chronic airway colonization status where documented, such as Pseudomonas aeruginosa
• Comorbidities including CF-related diabetes and CF liver disease; pediatric and adult age bands
• Matched healthy controls available

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed cystic fibrosis donors
• Processed within one day of collection
• Cryopreserved for long-term stability
• IRB-approved protocols and electronic informed consent
• Custom aliquot volumes available upon request

De-identified Donor Data

• Verified cystic fibrosis diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Genotype and modulator therapy status where available
• Additional cystic fibrosis-specific metadata available on request

Applications

• Circulating inflammatory cytokine and acute-phase protein profiling
• Plasma proteomics and biomarker discovery
• Metabolomic and lipidomic analysis of malabsorption and nutritional status
• Fat-soluble vitamin and micronutrient analyte research
• Pharmacodynamic and treatment-response studies around CFTR modulator therapy
• Genotype-stratified biomarker comparisons
• Assay development and validation using disease-state plasma matrix
• Comorbidity research including CF-related diabetes and liver involvement

Other Cystic Fibrosis Specimen Types

• Cystic Fibrosis Serum
• Cystic Fibrosis Whole Blood
• Cystic Fibrosis PBMC
• Cystic Fibrosis Leukopak

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Cystic Fibrosis Plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse all matrices and disease states, visit our human plasma page.